Scott Kopetz

Scott Kopetz at MD Anderson Cancer Center led the BEACON CRC trial establishing encorafenib plus cetuximab as standard of care for BRAF V600E colorectal cancer, overcoming decades of failed BRAF inhibitor monotherapy in this molecular subset. His laboratory work identified the feedback reactivation mechanism of EGFR that renders single-agent BRAF inhibition ineffective in colorectal cancer and rationalized combination strategies. He has contributed to ctDNA-guided therapy selection in colorectal cancer and molecular characterization of resistance. He is among the most influential precision oncology researchers in gastrointestinal malignancies.